Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

4DMT's 4D-150 Demonstrates Durable, Multi-Year Benefit Supporting Its Potential As A Backbone Therapy For Wet AMD And Retinal Diseases

Author: Benzinga Newsdesk | November 06, 2025 06:14am

4D-150 demonstrated consistent and durable benefit across all three patient cohorts as evidenced by maintenance of visual acuity, control of retinal anatomy and reduction of treatment burden at all time points with up to 2 years of follow-up
Strong dose response in favor of Phase 3 dose (3E10 vg/eye) continues to be demonstrated
4D-150 continues to be well tolerated with no new safety or intraocular inflammation findings, consistent with previous updates, with up to 3.5 years of follow-up
4FRONT-1 Phase 3 enrollment continues to exceed initial expectations, with over 200 patients randomized to date; the global 4FRONT-2 Phase 3 clinical trial enrollment remains on track for expected completion in H2 2026

Posted In: FDMT